Highbridge Capital Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-3,907,852
| Closed | -$4.62M | – | 103 |
|
|
2019
Q4 | $4.62M | Buy |
3,907,852
+47,598
| +1% | +$36.5K | 0.51% | 43 |
|
|
2019
Q3 | $2.18M | Buy |
3,860,254
+31,470
| +0.8% | +$16.9K | 0.32% | 42 |
|
|
2019
Q2 | $2M | Sell |
3,828,784
-5,779,569
| -60% | -$2.89M | 0.13% | 91 |
|
|
2019
Q1 | $4.33M | Buy |
9,608,353
+113,986
| +1% | +$53.2K | 0.13% | 167 |
|
|
2018
Q4 | $4.56M | Buy |
9,494,367
+593,486
| +7% | +$295K | 0.13% | 168 |
|
|
2018
Q3 | $4.68M | Buy |
8,900,881
+835,531
| +10% | +$448K | 0.11% | 216 |
|
|
2018
Q2 | $3.99M | Buy |
8,065,350
+651,755
| +9% | +$304K | 0.08% | 291 |
|
|
2018
Q1 | $3.11M | Buy |
7,413,595
+400,000
| +6% | +$161K | 0.05% | 375 |
|
|
2017
Q4 | $2.66M | Buy |
7,013,595
+2,497,879
| +55% | +$948K | 0.05% | 346 |
|
|
2017
Q3 | $1.6M | Buy |
4,515,716
+645,951
| +17% | +$239K | 0.02% | 479 |
|
|
2017
Q2 | $1.45M | Buy |
3,869,765
+559,890
| +17% | +$229K | 0.02% | 495 |
|
|
2017
Q1 | $1.44M | Buy |
3,309,875
+65,338
| +2% | +$28.7K | 0.02% | 518 |
|
|
2016
Q4 | $1.2M | Buy |
3,244,537
+2,216,137
| +215% | +$750K | 0.02% | 502 |
|
|
2016
Q3 | $278K | Buy |
+1,028,400
| New | +$260K | ﹤0.01% | 1043 |
|
|
2013
Q4 | – | Sell |
-1,250,000
| Closed | -$2.52M | – | 1628 |
|
|
2013
Q3 | $2.52M | Sell |
1,250,000
-100,000
| -7% | -$190K | 0.03% | 465 |
|
|
2013
Q2 | $2.56M | Buy |
+1,350,000
| New | +$2.37M | 0.03% | 436 |
|
Highbridge Capital Management's GCVRZ Position: Q1 2020 in Review
Highbridge Capital Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 3,907,852 shares — an estimated $4.62M sold.
Highbridge Capital Management first reported a position in GCVRZ in Q2 2013 and held it in 16 quarters. The position peaked at $4.68M in Q3 2018. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- Highbridge Capital Management reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- Highbridge Capital Management sold 3,907,852 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $4.62M.
- Highbridge Capital Management first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 16 quarters.
- Highbridge Capital Management's Sanofi Contingent Value Rights position peaked at $4.68M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on Highbridge Capital Management's 13F filing for Q1 2020, filed 15 May 2020.